Paracetamol in osteoarthritis of the knee

Annals of the Rheumatic Diseases
C Miceli-RichardM Dougados

Abstract

Paracetamol is a recommended symptomatic treatment of osteoarthritis (OA), but in clinical trials sample sizes have been relatively small and variable daily doses of paracetamol have been used. To determine the therapeutic efficacy of paracetamol in OA of the knee and identify predictive factors of clinical response to treatment. A double blind, parallel group, placebo controlled trial of analgesic efficacy and safety of paracetamol versus placebo including 779 patients with OA of the knee. Patients were randomly assigned to receive paracetamol 4 g/day (n = 405) or placebo (n = 374) for 6 weeks. Symptomatic OA of the knee was required at inclusion with global pain intensity of the knee during physical activities for the past 24 hours of >or=30 mm on a 100 mm visual analogue scale. The primary end point was a 30% decrease of global pain intensity of the knee. Intention to treat analyses were performed. The percentage of responders did not differ significantly between groups: 52.6% and 51.9% in paracetamol and placebo groups, respectively (p = 0.840). In a subgroup of patients with chronic mechanical knee pain without signs of inflammation (n = 123), the mean change in pain intensity from baseline was 25.2 mm v 15.2 mm, in the pa...Continue Reading

References

Apr 25, 2001·American Journal of Therapeutics·L F Prescott
Dec 26, 2001·The New England Journal of Medicine·C M ForedO Nyrén
Jan 12, 2002·JAMA : the Journal of the American Medical Association·Gregory P GebaUNKNOWN Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group
Dec 1, 1957·Annals of the Rheumatic Diseases·J H KELLGREN, J S LAWRENCE
Dec 3, 2003·Annals of the Rheumatic Diseases·K M JordanUNKNOWN Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT

❮ Previous
Next ❯

Citations

Jan 22, 2005·American Journal of Therapeutics·Gregory M Peterson
Jan 22, 2005·American Journal of Therapeutics·C Jane NiklesDavid Wilkinson
Jul 14, 2004·Annals of the Rheumatic Diseases·R NeameM Doherty
Mar 25, 2006·British Journal of Sports Medicine·J Bjordal
Nov 26, 2008·Arthritis Research & Therapy·Francis Berenbaum
Jun 28, 2011·Journal of Pharmacology & Pharmacotherapeutics·Alpa Pragnesh Gor, Miti Saksena
Apr 1, 2006·Expert Review of Pharmacoeconomics & Outcomes Research·Mark Jc NuijtenHiltrud Liedgens
Apr 1, 2014·Expert Review of Clinical Pharmacology·Marissa BliedenRami Ben-Joseph
Nov 18, 2015·Basic & Clinical Pharmacology & Toxicology·Zandra Nymand EnnisAnton Pottegård
Apr 14, 2015·Expert Opinion on Emerging Drugs·Shirley Pei-Chun Yu, David John Hunter
Oct 4, 2007·Journal of the American Geriatrics Society·Catherine H MacLeanKenneth G Saag
Nov 24, 2004·The Journal of Pain : Official Journal of the American Pain Society·Wendy P BattistiGregory P Geba
Sep 19, 2006·Best Practice & Research. Clinical Rheumatology·Peter JüniPaul Dieppe
Sep 17, 2005·The Orthopedic Clinics of North America·Bryan T Hanypsiak, Benjamin S Shaffer
Jan 26, 2011·Scandinavian Journal of Rheumatology·G F SnijdersUNKNOWN NOAC Study Group
Dec 2, 2014·Revista española de cirugía ortopédica y traumatología·M A Ruiz IbánE Loza
Dec 9, 2014·JAAPA : Official Journal of the American Academy of Physician Assistants·Cody Sasek
Aug 11, 2016·Archives of Orthopaedic and Trauma Surgery·Mario Simental-MendíaHerminia Guadalupe Martínez-Rodríguez
Sep 13, 2016·Biotechnology and Bioengineering·Marta OndrésikRui L Reis
Jun 21, 2006·Journal of Cardiovascular Pharmacology·Maxime Dougados
Jan 27, 2006·The Cochrane Database of Systematic Reviews·T E TowheedG Wells
Feb 26, 2019·The Cochrane Database of Systematic Reviews·Amanda O LeopoldinoManuela L Ferreira
Aug 22, 2020·Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders·Andriy M GnylorybovKnarik V Ginosyan
Mar 13, 2021·Advanced Therapeutics·Carlisle R DeJuliusCraig L Duvall
Aug 30, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabio ColellaLaura B Creemers

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.